Quick Facts: Therapeutic Domain

• Main Use: Supports the management of diabetes mellitus.
• Benefit: Helps to regulate blood glucose levels in adults and pediatric patients.
• Goal: Aims to improve overall glycaemic control.

---

Actraphane 30 FlexPen is an authorized therapeutic agent used for the management of diabetes mellitus. This condition is characterized by the body's inability to effectively manage its blood glucose (sugar) levels.

This medication contains a biphasic blend of human insulin. The composition includes a soluble (fast-acting) component and an isophane (longer-acting) component, working together to achieve a combined duration of effect. Its primary benefit is to help regulate the concentration of glucose in the bloodstream, working to support the necessary entry of glucose from the blood into the cells.

The initiation of treatment with this agent aims to support the patient in maintaining improved glycaemic control. Achieving and maintaining appropriate glycaemic control is generally considered crucial for promoting long-term well-being in individuals with diabetes, including both type 1 and type 2.

The treatment may help to reduce the level of glycosylated haemoglobin (HbA1c), which provides an indication of long-term blood glucose management. It is utilized when a therapeutic profile that offers both a rapid initial effect and a more prolonged duration of action is required.

Regulatory References

1. EMA therapeutic overview

Eligibility Map: Who Can and Cannot Use Actraphane 30 FlexPen — Official Regulatory Information

This map details the population-eligibility and non-eligibility rules for Actraphane 30 FlexPen, based strictly on the content of official governmental regulatory documents, primarily the EMA Summary of Product Characteristics (SmPC).

Category	Regulatory Statement
Populations for whom use is allowed (as stated in label)	Patients with Diabetes Mellitus (Type 1 and Type 2); Adults, Children and Adolescents, and Elderly (ge 65 years old).
Populations for whom use is contraindicated	Patients with known hypersensitivity to human insulin or any excipient.
Condition-specific eligibility rules	Patients with Renal (Kidney) impairment and Hepatic (Liver) impairment are eligible, but glucose monitoring must be intensified.
Eligibility-related restrictions	Must not be injected in case of hypoglycaemia or if hypoglycaemia is suspected.
Pregnancy and lactation eligibility status	Pregnancy and Lactation are not restricted; monitoring is recommended for pregnant women.

---

Eligibility Classifications (High-Level)

Classification	Regulatory Statement
Eligibility severity classification	Contraindicated (Hypoglycaemia, Hypersensitivity) / Conditional Use (Renal/Hepatic impairment) / Approved (General, Paediatric, Elderly, Pregnancy, Lactation).
Regulatory basis	European Medicines Agency (EMA) Summary of Product Characteristics (SmPC).

---

Connection to the Overall Eligibility Profile

Regulatory documents establish that while Actraphane 30 FlexPen is an approved treatment for diabetes across all age groups, its use is strictly prohibited under two specific conditions: existing low blood sugar and known hypersensitivity. Eligibility for use in special populations, such as those with impaired kidney or liver function and older adults, is formally conditioned by the regulatory requirement for intensified blood glucose monitoring. The official profile defines eligibility based on a balance of broad age-group inclusion versus non-negotiable metabolic and hypersensitivity exclusions.

Interactions with other medicines and products

Interactions with Actraphane 30 FlexPen (human insulin) primarily involve pharmacodynamic effects that alter the patient's requirement for insulin to maintain blood glucose balance. These interactions are classified based on their potential to either intensify or reduce the glucose-lowering action.

Documented Pharmacodynamic Interactions

Interaction Type	Examples (Official Regulatory Listing)
May Reduce Insulin Requirement (Intensify Effect)	Oral Antidiabetic Agents, Monoamine Oxidase Inhibitors (MAOI), Non-selective Beta-blocking agents, ACE Inhibitors, Salicylates, Anabolic Steroids, Sulfonamides.
May Increase Insulin Requirement (Reduce Effect)	Oral Contraceptives, Thiazides, Glucocorticoids, Thyroid Hormones, Beta-sympathomimetics, Growth Hormone, Danazol.

Specific Substance Interactions and Restrictions

Co-administration with Beta-blocking agents is documented to potentially mask the typical symptoms of hypoglycaemia.

The effect of alcohol is officially described as variable, having the potential to either intensify and prolong or reduce the hypoglycaemic effect of insulin.

The regulatory label advises close observation when co-administering insulin with Pioglitazone (a thiazolidinedione) due to documented reports of cardiac failure in patients with pre-existing risk factors. If cardiac symptoms worsen, the official recommendation is to discontinue Pioglitazone.

Physiological factors such as renal or hepatic impairment are also noted to potentially reduce the patient's insulin requirements.

Actraphane 30 FlexPen delivers human insulin, a biphasic suspension composed of 30% soluble (rapid-acting) insulin and 70% isophane (intermediate-acting) insulin.

Molecular and Cellular Action

Human insulin acts as an agonist at the Insulin Receptor (IR), a cell-surface tyrosine kinase receptor present on key target tissues, including skeletal muscle, adipose tissue, and the liver. Binding of insulin to the extracellular alpha-subunits of the IR induces a conformational change that activates the intrinsic tyrosine kinase activity in the intracellular beta-subunits. This activation triggers autophosphorylation and the subsequent phosphorylation of intracellular substrates, notably Insulin Receptor Substrate (IRS) proteins.

Intracellular Cascades and Systemic Effects

IRS protein phosphorylation activates the PI3K/Akt signaling cascade. Activation of the Akt pathway leads to the translocation of Glucose Transporter type 4 (GLUT4) vesicles to the plasma membrane in muscle and adipose cells, resulting in a facilitated increase in glucose uptake from the systemic circulation. Concurrently, in the liver, insulin signaling modulates enzyme activity, inhibiting glycogenolysis and gluconeogenesis and promoting glycogenesis. The isophane component, complexed with protamine and zinc, is absorbed more slowly from the subcutaneous depot, providing a protracted activation of these same pathways. The net system-level physiological consequence is the modulation of whole-body glucose homeostasis.

Administration Overview

Actraphane 30 is a premixed insulin suspension intended for subcutaneous injection. This delivery system consists of a pre-filled, multidose, disposable pen designed for use with compatible single-use needles. Proper preparation of the suspension and correct injection technique are necessary for the effective management of blood glucose levels.

Preparation of the Suspension

Before using the pen for the first time, the insulin must be brought to room temperature. The suspension inside the pen should appear uniformly white and cloudy after resuspension. This is achieved by rotating the pen between the palms and moving it up and down so that the glass ball inside moves from one end to the other. This process must be repeated until the liquid is consistently mixed. For subsequent injections, the mixing procedure must be performed again immediately before the dose is delivered.

Injection Technique

The insulin is administered via injection into the subcutaneous layer of the skin. Common injection sites include the abdomen, the buttocks, the front of the thighs, or the upper arms. The choice of site affects the speed at which the insulin enters the bloodstream. To reduce the risk of skin changes such as lumps or pits at the injection site, the specific point of injection should be rotated within the chosen anatomical area for every dose.

Use of the Pen and Needles

The device is designed to be used with specific disposable needles. A new, sterile needle must be attached before every injection to prevent contamination and to ensure the delivery of the correct dose. Once the injection is complete, the needle should be removed and disposed of safely. The pen should not be stored with the needle attached, as this can lead to insulin leakage or the formation of air bubbles.

Maintenance and Handling

The pen is for individual use only and must not be shared between different people. It is important to check the label before use to ensure the correct insulin type is being administered. If the insulin does not appear uniformly white and cloudy after the mixing process, the pen should not be used. Additionally, the device should be protected from excessive heat and light during daily use.

Research Evidence / Overview of Studies for Actraphane 30 FlexPen

---

Study Types and Primary Focus in Diabetes Management

The evidence base for Actraphane 30 FlexPen, a premixed human insulin, was studied for the management of diabetes mellitus. This research was evaluated in the context of the condition, which involves systemic or functional imbalance.

The research primarily involves Randomized Controlled Trials (RCTs). These short-term RCTs research examined comparison groups that used other insulin preparations, including newer insulin analogues, allowing researchers to monitor blood sugar patterns. Furthermore, specialized Pharmacokinetic/Pharmacodynamic (PK/PD) studies were observed in participants. These intensive studies research examined how quickly the insulin is absorbed and the duration of its activity (its action profile) over defined time intervals. Separate studies were also conducted to evaluate the dose consistency and accuracy of the FlexPen delivery device.

The therapeutic class (human biphasic insulin) has a long history of use and its core evidence consists mainly of RCTs and observational data.

---

Evaluation of Efficacy Markers in Type 1 and Type 2 Diabetes

Research was conducted for both Type 1 Diabetes and Type 2 Diabetes. The main clinical outcome that researchers monitored was Glycosylated Haemoglobin (HbA1c) levels, a laboratory measurement for blood sugar status. Additional studies monitored daily measures such as Fasting Blood Glucose (FBG) and Postprandial Glucose (PPG) levels.

The comparative trials research examined short-term changes in the HbA1c marker. Research focusing on postprandial (after-meal) blood sugar documented patterns of regulation relative to the specific conditions under which they were conducted. These findings describe patterns observed in the studies.

---

Research Gaps and Key Limitations

A key limitation is that the primary comparative efficacy trial had a short duration (12 weeks), and the sample sizes were modest when measured against the long-term commitment required for managing this condition. Furthermore, comparative evidence is lacking in some areas, as studies often involve comparisons against newer insulin analogues, meaning the direct comparison of all outcomes may be limited.

Data for certain groups remain insufficient to draw broad conclusions. The long-term effects are not fully established by these specific short-term RCTs, and certainty remains low for outcomes extending beyond the observation period.

Common questions about Actraphane 30 FlexPen (FAQ)

---

Q: How quickly does Actraphane 30 FlexPen typically start to work?

Official product information, based on its specific formulation, indicates that Actraphane 30 FlexPen typically begins to lower blood glucose levels approximately 30 minutes after it is administered as a subcutaneous injection.

Q: How long does the effect of Actraphane 30 FlexPen usually last?

Due to its biphasic composition (containing both fast- and intermediate-acting insulin), the total duration of action for Actraphane 30 FlexPen is stated in official regulatory documents to last for approximately 24 hours.

Q: What is the purpose of the FlexPen device?

The FlexPen is a pre-filled, disposable pen device designed to deliver the insulin suspension. Its purpose, as a pen injector, is described as providing a measured, convenient, and consistent way to administer the required subcutaneous dose.

Q: Why does the pen have a suspension that needs mixing?

Actraphane 30 is a biphasic suspension, containing both soluble and isophane components. Regulatory guidelines state that the suspension must be resuspended to ensure the fixed-ratio components are uniformly mixed before administration, as the intermediate-acting component naturally settles.

Q: Is the Actraphane 30 FlexPen pre-filled or reusable?

Actraphane 30 is supplied as a pre-filled, disposable pen. Once the insulin is fully used or after the in-use stability period has passed (42 days), the entire pen should be discarded according to established medical waste disposal guidelines.

Q: Does the time of day matter when using Actraphane 30 FlexPen?

Official guidelines state the injection should be followed by a carbohydrate-containing meal or snack within 30 minutes. The timing of the injection is therefore generally tied to meal consumption, as per regulatory documents.

Q: Is it necessary to use a new needle every time with Actraphane 30 FlexPen?

Official usage instructions typically recommend the use of a new needle for each individual injection. Needles should be removed immediately after use and safely discarded according to sharps disposal guidelines.

Q: What is the typical timeframe for noticing an effect on HbA1c with Actraphane 30 FlexPen?

Clinical monitoring of blood sugar control is often tracked using the HbA1c marker. Changes in this long-term marker typically take 2 to 3 months to be fully noticeable after starting or adjusting any insulin treatment, based on the slow turnover of red blood cells.

Q: Is Actraphane 30 FlexPen the same as Novomix 30?

No, Actraphane 30 and NovoMix 30 contain different active ingredients. Actraphane 30 contains Insulin human, while NovoMix 30 contains the insulin analogue insulin aspart. Both are biphasic insulins with a 30/70 ratio, but they are based on different active substances.

Q: Are there specific food restrictions to follow when using Actraphane 30 FlexPen?

The official product label does not list specific food restrictions, though it emphasizes that the injection must precede a carbohydrate-containing meal. Official documents note that any changes to a patient's usual diet may necessitate an adjustment in the required insulin dosage.

Q: Can Actraphane 30 FlexPen cause weight gain?

Weight gain is listed in regulatory documentation as a common side effect of insulin therapy in general, which includes products like Actraphane 30 FlexPen.

Q: Are there any specific vitamins or supplements that interact with Actraphane 30 FlexPen?

Regulatory documents do not systematically list interactions with vitamins and supplements. Official guidance generally advises caution, as some products may impact blood glucose levels and potentially require an insulin dose adjustment.

Q: Can emotional stress affect how Actraphane 30 FlexPen works?

While emotional stress is not listed as a direct drug interaction, regulatory warnings note that changes due to concomitant illness and other major physiological or lifestyle changes can affect blood glucose levels and may require a dosage change.

Q: What should I do if the appearance of the Actraphane 30 FlexPen looks different?

Before every use, the suspension must be visually inspected and must appear uniformly white and cloudy after mixing. If the insulin looks clear, contains solid clumps, or appears otherwise abnormal, official instructions advise that the product should not be used and should be discarded.

Q: What are the general expectations for blood sugar control when starting Actraphane 30 FlexPen?

The general therapeutic expectation is the overall modulation of whole-body glucose homeostasis leading to improved blood sugar balance. Official documentation notes that intensified blood glucose monitoring and potential dose adjustments are often necessary, especially when starting or changing therapy.

Q: Why is Actraphane 30 FlexPen administered by injection and not as a pill?

Insulin is a protein hormone. If it were swallowed as a pill, digestive enzymes in the stomach and intestines would break down the protein before it could be absorbed into the bloodstream and take effect.

Q: What are the potential interactions with herbal remedies and Actraphane 30 FlexPen?

Specific data on interactions with herbal remedies is limited. Official guidance suggests that certain herbal products may possess blood glucose-lowering effects that could necessitate an adjustment in the prescribed insulin dose.

Q: Can Actraphane 30 FlexPen be used in patients with liver impairment?

Yes, it can be used in patients with hepatic (liver) impairment. However, regulatory documents advise that monitoring should be intensified in these patients, as liver impairment is noted to potentially reduce the patient's insulin requirements.

Q: Can using Actraphane 30 FlexPen cause blurred vision?

Temporary blurred vision is a potential symptom that may occur during an episode of hypoglycaemia (low blood glucose), which is a very common side effect of insulin therapy, particularly during the initial phase of improving blood sugar control.

Q: Are there guidelines regarding exercise when using Actraphane 30 FlexPen?

Official documentation notes that unplanned, strenuous physical exercise may lead to low blood sugar (hypoglycaemia). Dosage adjustment may also be necessary if a patient changes their routine level of physical activity.

Q: Does Actraphane 30 FlexPen interact with oral contraceptives?

Yes, official regulatory documents list Oral Contraceptives as medicines that may increase the patient’s insulin requirement. This means that co-administration may necessitate a dose adjustment to maintain adequate glucose control.

Storage and Stability Requirements

Unopened Pens (Not in Use)

Condition	Requirement	Shelf-Life Constraint
Temperature	Store in a refrigerator (2 C to 8 C).	Potent until the expiration date on the label.
Prohibition	The product must never be frozen; frozen insulin must be discarded.	Not applicable.

In-Use Pens (Opened)

Condition	Requirement	Stability Period
Temperature	Store at room temperature, not exceeding 30 C.	Maximum of 42 days after first use.
Protection	Keep the pen cap on to protect the insulin from light.	The pen must be stored without a needle attached.

Official Disposal and Handling

• Child Safety: Keep the medicinal product out of the sight and reach of children.
• Sharps Disposal: Used needles and sharps must be placed immediately into a puncture-resistant sharps container.
• Unused Product: Any unused or expired FlexPen device must be discarded according to local regulatory requirements for medicinal waste. Do not dispose of loose needles or the device in household trash.